.INVESTIGATION FEATURE.16 October 2024. In the NIAGARA hearing, the add-on of perioperative durvalumab to conventional therapy for muscle-invasive sac cancer cells strengthened event-free as well as on the whole survival, marking a new procedure choice for this ailment.